Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CheckMate 914 trial, which explored the efficacy of adjuvant nivolumab plus ipilimumab vs placebo in the treatment of patients with localized renal cell carcinoma who are at high risk of relapse...
Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses health-related quality-of-life data from the phase III CLEAR trial, which compared lenvatinib plus pembrolizumab or everolimus vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (Abstract...
In a phase III clinical trial of patients with previously untreated metastatic renal cell cancer combining the immunotherapy atezolizumab (Tecentriq) with the targeted therapy bevacizumab (Avastin) delayed cancer growth by about 3 months longer than sunitinib, another targeted therapy. The benefit...
As reported in the Journal of Clinical Oncology by Motzer et al, the phase III PROTECT trial showed no significant disease-free survival benefit for adjuvant pazopanib at 600 mg vs placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma at high risk of relapse. ...
Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses the results of this study, which could well change the treatment paradigm in patients with previously treated metastatic renal cell carcinoma (Abstract 3LBA).
In a phase II trial reported in The Lancet Oncology, Motzer et al found that the combination of the multi–tyrosine kinase inhibitor lenvatinib (Lenvima) plus the mTOR inhibitor everolimus (Afinitor) significantly improved progression-free survival vs everolimus alone in patients with...
In a randomized phase II trial reported in the Journal of Clinical Oncology, Motzer et al found that the PD-1 immune checkpoint inhibitor antibody nivolumab was associated with antitumor activity and manageable toxicity at three dose levels in patients with metastatic renal cell carcinoma who had...
As reported by Motzer et al in the Journal of Clinical Oncology, the randomized phase II RECORD-3 trial showed that first-line use of everolimus did not achieve noninferiority in progression-free survival vs sunitinib (Sutent) in patients with metastatic renal cell carcinoma receiving sequential...
A phase III trial reported in 2013 showed noninferiority of pazopanib (Votrient) vs sunitinib (Sutent) for progression-free survival in first-line treatment of clear cell metastatic renal cell carcinoma. In a letter to the editor in The New England Journal of Medicine, Motzer et al provided the...
Fibroblast growth factor (FGF) pathway activation may be a mechanism of escape from vascular endothelial growth factor (VEGF)-targeted therapies. In a phase III trial reported in The Lancet Oncology, Motzer et al compared the VEGF and FGF receptor tyrosine kinase inhibitor dovitinib vs sorafenib...
Tivozanib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. In a phase III trial reported in Journal of Clinical Oncology by Robert J. Motzer, MD, of Memorial Sloan-Kettering Cancer Center (MSKCC) and colleagues, tivozanib was found to...